• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Amyloidosis - Articles and news items

Amyloidosis - Printed Diagnosis with Mint Green Pills, Injections and Syringe

Prothena’s 2016 2nd quarter results support advancement of multiple clinical development programs

Industry news / 3 August 2016 / Prothena Corporation plc

Prothena Corporation plc has reported financial results for the second quarter and first six months of 2016. In addition, the Company provided an update on its R&D programs and 2016 financial guidance…

Genzyme opts into Alnylam’s ALN-AT3 haemophilia programme

Industry news / 1 October 2015 / Victoria White

Genzyme has elected to opt into the programme for development and potential future commercialisation of ALN-AT3 in territories outside of North America and Western Europe…

Takeda submits NDA in the US for ixazomib for the treatment of multiple myeloma

Industry news / 15 July 2015 / Victoria White

Takeda has submitted an NDA to the US FDA for ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma…

Alnylam receives Orphan Drug Designation for revusiran for the treatment of ATTR amyloidosis

Industry news / 21 May 2015 / Victoria White

The FDA has granted Orphan Drug Designation to Alnylam’s revusiran for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)…

First patient enrolled in Phase 3 study of ixazomib as maintenance therapy for newly diagnosed multiple myeloma

Industry news / 12 May 2015 / Victoria White

Takeda has announced that the first patient has been enrolled in the Phase 3 TOURMALINE-MM4 study of investigational oral ixazomib…

Prothena initiates NEOD001 global Phase 3 registrational trial

Prothena initiates NEOD001 global Phase 3 registrational trial based on positive results in ongoing phase 1/2 study

Industry news / 3 December 2014 / Prothena

Prothena initiates NEOD001 global Phase 3 registrational trial based on positive results in ongoing phase 1/2 study of NEOD001 in Patients With AL Amyloidosis…

Pfizer logo

FDA issues complete response letter for Pfizer’s tafamidis meglumine New Drug Application

Industry news, News / 18 June 2012 / Pfizer

Tafamidis is a novel, investigational medication for the treatment of TTR-FAP…

Pfizer logo

FDA accepts Pfizer’s New Drug Application for Tafamidis Meglumine

Industry news, News / 15 February 2012 / Pfizer

A novel, investigational treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +